Alpizar-Rodriguez, A., Förger F. et al.: Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort. Rheumatology, Oct 2018

Lauper K., Mongin D., Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD Open, Sept. 2018

Oude Voshaar M. A. H., Dourvoisier D., van de Laar M.A.F.J. et al: Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric. Quality of Life Research, September 2018

Lechtenböhmer C.A., Hügle T. et al: Influence of Disease Activity in Rheumatoid Arthritis on Radiographic Progression of concomitant Interphalangeal Joint Osteoarthritis. Arthritis and Rheumatology, August 2018

Didden E.M., Egger M., Finckh A. et al: Prediction of Real-World Drug Effectiveness Pre-Launch: Case Study in Rheumatoid Arthritis. Medical Decision Making, August 2018

Martinez-Prat L., Nissen M.J. et al: Comparison of serological Biomarkers in rheumatoid arthritis and their combination to improve Diagnostic Performance. Frontiers in Immunology, June 2018

Lauper K., Gabay C., et al: Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic DMARDs in patients with rheumatoid arthritis after the use of at least one biologic DMARD: analyses from the pan-European TOCERRA register collaboration. Ann Rheum Dis. May 2018; 0:1-7, doi: 10.1136/annrheumdis-2017-212845

Müller, R.B., von Kempis, J. et al: Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort. Rheumatic and muscosceletal diseases (RMD) open, May 2018

Hebeisen, M., Ciurea A., et al.: Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. J Rheumatol. 2018 Apr;45(4):506-512. doi: 10.3899/jrheum.170166

Lauper K., Gabay C., et al: Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Arthritis Care Res. Apr. 2018, doi: 10.1002/acr.23567

Heinimann, K., von Kempis, J., et al.: Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort. J Clin Med. 2018 Mar 13;7(3). pii: E57. doi: 10.3390/jcm7030057

Zufferey P., Ziswiler HR, A. et al: Can Ultrasound Be Used to Predict Loss of Remission in Patients with RA in a Real-life Setting? A Multicenter Cohort Study. The Journal of Rheumatology 2018; 45:3; doi:10.3899/jrheum.161193

Molnar, C., Scherer, A. et al.: TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2017 Sep 22. pii: annrheumdis-2017-211544. doi: 10.1136/annrheumdis-2017-211544. [Epub ahead of print]

Micheroli, R., Hebeisen, M., Ciurea, A. et al.: Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther. 2017 Jul 19;19(1):164. doi: 10.1186/s13075-017-1372-3.

Stekhoven, D., Scherer, A., Nissen, M.J. et al.: Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clin Rheumatol (2017), doi:10.1007/s10067-017-3637-2, 22 April 2017

Chaigne B et Finckh A et al: Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life. Qual Life Res. 2017 Mar 11. doi: 10.1007/s11136-017-1534-4. [Epub ahead of print]

Chatzidionysiou K and Gabay C et al: Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. J Rheumatol. 2017 Feb;44(2):162-169. doi: 10.3899/jrheum.160460. Epub 2017 Jan 15.

Iannone F and Finckh A et al: Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA). Clin Rheumatol. 2016 Dec 14. PMID: 27966068 DOI: 10.1007/s10067-016-3505-5 [Epub ahead of print]

Mueller RB et al, “Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)”. Clin Rheumatol. 2016 Nov 12. [Epub ahead of print]

Nissen MJ et al: “The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.” Arthritis Rheumatol. 2016 Sep;68(9):2141-50. doi: 10.1002/art.39691.